McKenna's Drug Handbook for Nursing & Midwifery, 7e

1300      Miscellaneous drug categories

Action Paramagnetic contrast agent used for imaging of intracranial and spinal lesions in presence of abnormal blood–brain barrier or abnormal vascularity.

• Gadodiamide may interfere with calcium and other electrolyte measurements for up to 24 hours. • Closelymonitor individualfordevelopment of anaphylactic reaction. Ensure emergency management equipment is available and in correct working order. • Monitor vital signs closely following procedure. Patient teaching • Advise person to report any adverse effects. gadopentetate Magnevist Pregnancy risk category B2 Use in sport: Permitted Available forms Single-usevial: 469mg/mL (0.5mmol/mL) in 5 mL, 10 mL, 15 mL, 20 mL, 30 mL Prefilled syringe: 469 mg/mL in 10 mL, 15 mL, 20 mL Indications & dosages ➤ EnhancementofCNSorwhole-bodyMRI— Adultsandchildrenover2years: 0.1mmol/ kgbodyweight(0.2mL/kgbodyweight)by IV bolus or infusion. Action Paramagnetic contrast agent used for imag­ ing of intracranial and spinal lesions in presence of abnormal blood–brain barrier or abnormal vascularity, as well as whole- body imaging.

Route Onset

Peak

Duration

IV

Immediate Unknown 24 hrs

Adverse reactions CNS: ataxia, light-headedness, somnolence, tremor. CV: angina pectoris, arrhythmias, cardiac arrest , circulatory failure , hypertension, hypotension, tachycardia, vasodilation. ENT: tinnitus. Eye: visual disturbance. GI: abdominal pain, diarrhoea, dry mouth, faecal incontinence, nausea, taste alteration. GU: acute kidney injury , urinary incontin­ ence. Musculoskeletal: myalgia, nephrogenic systemic fibrosis . Psychiatric: anxiety, personality disorder. Respiratory: dyspnoea, rhinitis. Skin: flushing, rash, pruritus, urticaria. Other: anaphylactic reaction , hyper­ sensitivity, injection site pain. Interactions None reported. Contraindications Contraindicated in individuals with known hypersensitivity to the preparation; in individuals with acute or chronic severe renal insufficiency or renal insufficiency due to hepatorenal syndrome; and in the perioperative period in liver transplantation. care considerations • Increased risk of nephrogenic systemic fibrosis in individuals with acute or chronic renal failure or acute renal insufficiency, or during the perioperative period in liver transplantation. Renal function should be assessed in all individuals prior to the procedure.

Route Onset

Peak

Duration

IV

Immediate Unknown 24 hrs

Adverse reactions CNS: burning sensation, coma , convulsions, dizziness, dysgeusia, headache, loss of consciousness , paraesthesia, somnolence, syncope, tremor.

Reactions may be common , uncommon, life-threatening , or commonandlife-threatening.